Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 11/20 | 0.41 |
| ▸ | PAK4 | O96013 | 3/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018595 | 0.85 | HPGDS (0.56) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| SCHEMBL22975471 | 0.82 | HPGDS (0.60) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| SCHEMBL17731711 | 0.81 | HPGDS (0.58) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| SCHEMBL1071001 | 0.79 | ADORA1 (0.56) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| SCHEMBL28601840 | 0.79 | JAK3 (0.55) | JAK3JAK1BTK | |
| SCHEMBL28601837 | 0.79 | JAK3 (0.55) | JAK3JAK1BTK | |
| SCHEMBL22497059 | 0.76 | PAK4 (0.46) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| SCHEMBL22497061 | 0.76 | PAK4 (0.46) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| Hydrochloric Acid SCHEMBL22496764 | 0.75 | PAK4 (0.45) | ADORA1ADORA3ADORA2AADORA2BHPGDS | |
| Hydrochloric Acid SCHEMBL22496762 | 0.75 | PAK4 (0.45) | ADORA1ADORA3ADORA2AADORA2BHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ADORA1 4697/4885ADORA3 2289/4885ADORA2A 4661/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ADORA1 4697/4885ADORA3 2289/4885ADORA2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.